2- Tuesday Pharmacy Practice News – 6th July

1 – Attitudes, barriers and facilitators of hospital pharmacists conducting practice-based research: a systematic review

• Practice-based research is essential in enhancing medication knowledge, quality use of medicines, the scope of the pharmacy profession and improving patient outcomes.
• This systematic review aims to uncover the attitudes of hospital pharmacists towards practice-based research and their perceptions of the barriers and facilitators to undertaking practice-based research.

Source: Wiley Online Library

2 – Summaries of safety labeling changes approved by FDA—Boxed warnings highlights, January–March, 2021

• As part of FDA’s MedWatch program, important changes  to the safety labeling of drugs and therapeutic biologicals, including boxed warnings, are posted on the agency’s website.
• Boxed warnings are ordinarily used to highlight
  • (1) an adverse reaction so serious in proportion to the potential benefit from the drug that it is essential that the reaction be considered in assessing the risks and benefits of using the drug,
  • (2) serious adverse reactions that can be prevented or reduced in frequency or severity by appropriate use of the drug, and
  • (3) situations in which FDA approved a drug with restrictions to ensure safe use.

Source: ASHP

3 – Pharmacist outreach Program for COVID-19 monoclonal antibody distribution

• Deaths in the United States attributed to coronavirus disease 2019 (COVID-19) have recently surpassed 500,000, and vaccines are actively being distributed and administered, which promises to mitigate the number of future hospitalizations and deaths.
• The announcement of emergency use authorization (EUA) for the first COVID-19 monoclonal antibody (mAb) product, bamlanivimab, which helped to fill this niche, also created many logistical and ethical challenges for hospitals in the midst of many other competing priorities brought on by the COVID-19 pandemic.
• Recognizing the potential key benefit of mAb therapy in mitigating hospitalizations among high-risk patients before vaccine uptake, Nebraska Medicine drew on prior pandemic planning expertise and assembled a multidisciplinary team to prioritize and operationalize the offering and administration of bamlanivimab to patients.

Source: ASHP

4- Implementing a pharmacist-led transition of care model for post transplant hyperglycemia

• The implementation of a pharmacist-managed transition of care program for kidney transplant recipients with posttransplant hyperglycemia (PTHG) is described.
• A collaborative practice agreement was created and successfully implemented.
• A pharmacist-managed PTHG program could be incorporated into the standard care of kidney transplant recipients to help minimize rehospitalizations due to hyperglycemia.

Source: ASHP

5 – The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events

• Immune checkpoint inhibitors (ICIs) are an emerging treatment in cancer therapy for prolonging life, minimizing symptoms, and selectively targeting cancer.
• This study aims to compare the pattern of nivolumab-induced adverse events observed in practice, when compared with clinical trial and literature data.
• The secondary aim of the study is to identify the presentation and treatment modalities initiated in practice.
• The listed prevalence of adverse events and practice strategies identified throughout this study highlights how pharmacists may assist in the identification of predictable ICI toxicities associated with gastrointestinal, endocrine, dermatological toxicities, and fatigue.

Source: Journal of Pharmacy Practice

6 – Dapaglifozin Found to be Well-Tolerated in Hospitalized Patients With COVID-19

• A recent study found that dapagliflozin (Farxiga; AstraZeneca), a sodium-glucose cotransporter-2 (SGLT2) inhibitor, was well-tolerated in hospitalized patients with COVID-19, and participating patients had fewer serious adverse events than those taking placebo.
• According to the ADA, DARE-19 is the first large randomized clinical trial to assess SGLT2 inhibitors, a medication class initially used to help lower blood glucose, in patients with and without type 2 diabetes who are hospitalized with COVID-19.
• The study found that treatment with dapagliflozin did not achieve statistically significant reduction in organ failure or death, nor did it significantly improve clinical recovery, compared with placebo.

Source: Pharmacy Times

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2020 Pharmacotherapy Daily News (FNN) ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Pharmacy Practice FNN E-News, for publication of:

Read & Download FNN Issue 8 of April 2020 FNN News